Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.

Molecular cancer research : MCR - 1 Nov 2018

Childress Merrida A, Himmelberg Stephen M, Chen Huiqin, Deng Wanleng, Davies Michael A, Lovly Christine M

Abstract excerpt

Oncogenic tyrosine kinase fusions involving the anaplastic lymphoma kinase (ALK) are detected in numerous tumor types. Although more than 30 distinct 5' fusion partner genes have been reported, treatment of ALK-rearranged cancers is decided without regard to which 5' partner is present. There is little data addressing how the 5' partner affects the biology of the fusion or responsiveness to ALK tyrosine kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ALK gene

Share to NIH 3T3 Cells

Share to Oncogene Proteins, Fusion

Share to Phenotype

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 30002191
DOI: 10.1158/1541-7786.MCR-18-0171
PMCID: PMC6214753

Genes

ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.PMID 30002191Read ↗

Catalog of 5’ Fusion Partners in ALK-positive NSCLC Circa 2020Semantic proximity Read ↗

Novel ALK fusion partners in lung cancerSemantic proximity Read ↗

Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapiesSemantic proximity Read ↗

Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many FacesSemantic proximity Read ↗

ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy.Semantic proximity Read ↗

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK geneSemantic proximity Read ↗

Detecting and targetting oncogenic fusion proteins in the genomic eraSemantic proximity Read ↗

Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancersSemantic proximity Read ↗

ALKoma: A Cancer Subtype with a Shared TargetSemantic proximity Read ↗

Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF ActivitySemantic proximity Read ↗

Variant ALK ‐fusion positive anaplastic large cell lymphoma ( ALCL ): A population‐based paediatric study of the NHL‐BFM study groupSemantic proximity Read ↗

Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.